LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Mobile Blood Gas Analyzer for Hospital POC Launched

By LabMedica International staff writers
Posted on 19 Jul 2012
Print article
AACC 2012: A mobile blood gas analyzer, together with a diverse portfolio of new diagnostics testing solutions is launched.

Roche Diagnostics (Basel, Switzerland) is showcasing its new technology at the annual American Association of Clinical Chemistry (AACC) meeting Expo in Los Angeles (CA, USA), which is taking place July 15-19, 2012.

The cobas b 123 POC system is a mobile blood gas analyzer that offers next-generation technology that helps ensure reliable performance by virtually eliminating the introduction of blood clots that can contribute to analyzer downtime and negatively impact patient care. The cobas b 123 POC system is designed for hospital point-of-care settings.

The analyzer features a four-level clot protection system that helps prevent clots that can lead to reagent pack failures—a major issue for healthcare facilities because replacing the pack takes time away from patient care and wastes usable reagent. The cobas b 123 POC system also offers automatic linearity testing and calibration to simplify both workflow and regulatory compliance.

The cobas p 312 preanalytical system offers sample management on a small footprint. This front-end automation solution offers comprehensive, vendor-neutral sample management for labs with limited floor space. The compact, standalone system performs sample registration, sorting, decapping, and archiving of all sample tubes—including chemistry, immunoassay, hematology, coagulation, and urinalysis—for the entire laboratory, including non-Roche equipment.

It has a throughput of up to 450 tubes per hour, the system is ideal for customers who are looking for an entry-level step into automation for preanalytical workflow.

The cobas CT/NG Test screens for Chlamydia and gonorrhea infection. A polymerase chain reaction (PCR)-based multiplex dual probe assay, this molecular test is used to screen and diagnose Chlamydia and gonorrhea infection in symptomatic and asymptomatic patients. It runs on the automated cobas 4800 system and offers excellent sensitivity and high specificity. The test uses male urine and self-collected vaginal swabs, which are the preferred specimen types according to the CDC. They show high sensitivity yet are less invasive and less painful to collect than urethral or endocervical samples and thus may help promote screening compliance.

Roche is a biotech company with differentiated medicines in oncology, virology, inflammation, metabolism, and CNS. The company is also a leader in in-vitro diagnostics, tissue-based cancer diagnostics, and a pioneer in diabetes management.

Related Links:

Roche



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more